Last reviewed · How we verify
REFRESH OPTIVE UD
REFRESH OPTIVE UD is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.
REFRESH OPTIVE UD is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | REFRESH OPTIVE UD |
|---|---|
| Sponsor | AbbVie |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This is a multi-ingredient ophthalmic lubricant containing carboxymethylcellulose sodium, glycerin, and polysorbate 80 that mimics natural tears. It works by providing sustained lubrication to the cornea and conjunctiva, reducing friction and protecting against further desiccation in dry eye disease. The formulation is preservative-free (UD = unit dose) to minimize ocular irritation.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Blurred vision
- Eye discomfort
Key clinical trials
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REFRESH OPTIVE UD CI brief — competitive landscape report
- REFRESH OPTIVE UD updates RSS · CI watch RSS
- AbbVie portfolio CI